In which population is methylprednisolone associated with increased toxicity?

Methylprednisolone, a corticosteroid used for its anti-inflammatory and immunosuppressive properties, has been associated with increased toxicity particularly in African American populations. This increased susceptibility can be attributed to various genetic factors that influence drug metabolism, sensitivity, and the pharmacodynamics of corticosteroids.

Research has shown that genetic variations in drug-metabolizing enzymes and receptors can affect how individuals respond to methylprednisolone, potentially leading to a higher incidence of adverse effects or a need for dosage adjustments. Additionally, socio-economic factors and access to healthcare can influence overall health outcomes in different populations.

In contrast, other ethnic groups may not experience the same heightened risk due to different genetic profiles and metabolic pathways. It's important for clinicians to consider these population-specific variations when prescribing methylprednisolone and to monitor for potential toxicities closely.